Table 2.
Differences between no surgery and surgery of new-onset breast cancer patients
| Parameter | No surgery n = 6,840 | Surgery n = 98,447 | p value |
|---|---|---|---|
| Age in years, mean (SD) | 82.1 (11.1) | 60.6 (12.6) | < 0.001 |
| Age groups | < 0.001 | ||
| Under 40 years, N (%) | 50 (1.1%) | 4476 (98.9%) | |
| 40–50 years, N (%) | 139 (0.9%) | 15,538 (99.1%) | |
| 50–75 years, N (%) | 907 (1.4%) | 66,013 (98.6%) | |
| Over 75 years, N (%) | 5744 (31.6%) | 12,420 (68.4%) | |
| Detected during screening, N (%) | 233 (3.4%) | 39,370 (40.0%) | < 0.001 |
| Socioeconomic status | < 0.001 | ||
| 0–9%, N (%) | 917 (8.8%) | 9465 (91.2%) | |
| 10–20%, N (%) | 774 (7.4%) | 9700 (92.6%) | |
| 20–30%, N (%) | 717 (7.0%) | 9588 (93.0%) | |
| 30–40%, N (%) | 665 (6.4%) | 9662 (93.6%) | |
| 40–50%, N (%) | 675 (6.4%) | 9912 (93.6%) | |
| 50–60%, N (%) | 685 (6.7%) | 9587 (93.3%) | |
| 60–70%, N (%) | 623 (6.0%) | 9688 (94.0%) | |
| 70–80%, N (%) | 594 (5.6%) | 10,056 (94.4%) | |
| 80–90%, N (%) | 595 (5.5%) | 10,199 (94.5%) | |
| 90–100%, N (%) | 595 (5.3%) | 10,590 (94.7%) | |
| Tumor stage | < 0.001 | ||
| Stage I, N (%) | 2394 (3.9%) | 58,617 (96.1%) | |
| Stage II, N (%) | 4446 (10.0%) | 39,830 (90.0%) | |
| Medical history | < 0.001 | ||
| No medical history, N (%) | 6562 (2.6%) | 91,299 (97.4%) | |
| Positive non-oncological medical history, N (%) | 247 (3.5%) | 6774 (96.5%) | |
| Positive oncological medical history, N (%) | 31 (0.5%) | 374 (92.3%) | |
| Hormone receptor status | |||
| Her2 receptor negative, N (%) | 6331(6.8%) | 86,808 (93.2%) | < 0.001 |
| Progesterone receptor positive, N (%) | 4636(6.5%) | 66,854 (93.5%) | 0.831 |
| Estrogen receptor positive, N (%) | 5820(6.7%) | 81,244 (93.3%) | < 0.001 |
| Triple negative | 128(3.3%) | 3757 (96.7%) | < 0.001 |
| Tumor grade | < 0.001 | ||
| Low grade, N (%) | 1910 (7.2%) | 24,757(92.8%) | |
| Intermediate grade, N (%) | 3505 (6.9%) | 47,590(93.1%) | |
| High grade, N (%) | 1425 (5.2%) | 26,100(94.8%) | |
| Histological tumor type | < 0.001 | ||
| No special type, N (%) | 5198 (6.1%) | 79,460 (93.9%) | |
| Lobular (ILC), N (%) | 1072 (8.5%) | 11,536 (91.5%) | |
| Both, N (%) | 91 (2.9%) | 3041 (97.1%) | |
| Mucinous, N (%) | 300 (14.6%) | 1756 (85.4%) | |
| Medullary, N (%) | 1(0.2%) | 594 (99.8%) | |
| Tubular, N (%) | 18(2%) | 898 (98.0%) | |
| Other, N (%) | 160 (12.1%) | 1162(87.9%) | |
| Hospital volume | 0.395 | ||
| Low volume | 662 (6.7%) | 9166 (93.3%) | |
| Average volume | 1649 (6.4%) | 24,302 (93.6%) | |
| High volume | 4529 (6.5%) | 64,979 (93.5%) | |
| Year of diagnosis | < 0.001 | ||
| 2011, N (%) | 792 (6.2%) | 11,908 (93.8%) | |
| 2012, N (%) | 798 (6.1%) | 12,180 (93.9%) | |
| 2013, N (%) | 800 (6.1%) | 12,290 (93.9%) | |
| 2014, N (%) | 833 (6.3%) | 12,332 (93.7%) | |
| 2015, N (%) | 815 (6.2%) | 12,329 (93.8%) | |
| 2016, N (%) | 870 (6.6%) | 12,324 (93.4%) | |
| 2017, N (%) | 961 (7.0%) | 12,700 (93.0%) | |
| 2018, N (%) | 971 (7.3%) | 12,384 (92.7%) | |
BCT breast-conserving therapy, N number, SD standard deviation, BIRADS breast imaging reporting and data system, ILS invasive lobular carcinoma